Trevi Therapeutics up as itch treatment succeeds in study

Trevi Therapeutics

29/06/2022 13:01

** Shares of biopharma co Trevi Therapeutics  TRVI.O  rise
9.4% to $2.21 premarket
    ** Co says its experimental oral candidate, haduvio, met
main goal of statistically significant reduction in worst itch
in mid-to-late-stage study in patients with Prurigo nodularis
 urn:newsml:reuters.com:*:nPn4czHfna
    ** Prurigo nodularis is a skin disease characterised by
itchy nodules which usually appear on the arms or legs
    ** Co is developing haduvio for prurigo nodularis and
chronic cough in idiopathic pulmonary fibrosis 
    ** Stock has more than doubled so far this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))